Moderna Covid-19 Vax Works Against New Variants

Moderna Covid-19 vaccine neutralized titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and South Africa.

Moderna, the US-based drugmaker reported that its Covid-19 vaccine can neutralize activity against first identified variants in the UK and South Africa.

Vaccination with the Moderna Covid-19 Vaccine produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and South Africa, respectively, the company said on the basis of a study.

Moderna Filing COVID-19 Vax for Emergency Use Authorization
Moderna Inc, which has reported its COVID-19 vaccine is 94 per cent effective, on Monday announced it is filing with US and European regulators for emergency use authorization.

‘Moderna Covid-19 vaccine neutralized titers against all key emerging variants tested, even the first identified variants in the UK and South Africa.’

However, the company also said it will test an additional booster dose of its Covid-19 vaccine (mRNA-1273) to study the ability to further increase neutralising titers against emerging strains beyond the existing primary vaccination series.

Second, the company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in South Africa.

The company is advancing mRNA-1273.351 into preclinical studies and a Phase 1 study in the US to evaluate the immunological benefit of boosting with strain-specific spike proteins.

WHO Experts to Provide Guidelines on Moderna's COVID Vaccine
World Health Organization (WHO) panel of vaccine experts is set to issue recommendations on Moderna's COVID-19 vaccine on Tuesday.

Moderna expects that its mRNA-based booster vaccine (whether mRNA-1273 or mRNA-1273.351) will be able to further boost neutralising titers in combination with all of the leading vaccine candidates.

"As we seek to defeat the Covid-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna Covid-19 vaccine should be protective against these newly detected variants," Stephane Bancel, Chief Executive Officer of Moderna, said in a statement.

Moderna's Covid Vaccine Under Probe for Allergic Reactions
Moderna, a US-based drugmaker received a report from California's health department that several individuals at one vaccination center in San Diego developed allergic reactions after first shot of covid-19 vaccine.

"Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants."

COVID-19 Vaccine Of Moderna Shows Good Efficacy In Clinical Trials
Moderna’s COVID-19 vaccine mRNA-1273,- shows an efficacy of 94.1 percent in preventing symptomatic COVID-19. Mild adverse reactions of the vaccine were fatigue, muscle aches, joint pain and headaches.

Source-IANS